ImageneBio Inc
IMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.69 | 1.02 | -0.17 | 2.27 |
| FCF Yield | -4.84% | -8.12% | -6.54% | -1.15% |
| EV / EBITDA | -25.87 | -11.79 | -15.69 | -154.44 |
| Quality | ||||
| ROIC | -27.51% | -41.47% | -46.44% | -15.34% |
| Gross Margin | 100.00% | 88.86% | -311.84% | -52.03% |
| Cash Conversion Ratio | 0.93 | 1.17 | 1.08 | 1.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.26% | -33.38% | 19.32% | 3,140,773.90% |
| Free Cash Flow Growth | 42.61% | -6.11% | -21.82% | -60.69% |
| Safety | ||||
| Net Debt / EBITDA | 0.90 | 1.47 | 0.77 | 6.70 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -739.30 | -11.88 | -18.47 |